Dose-finding designs for trials of molecularly targeted agents and immunotherapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose-finding designs for trials of molecularly targeted agents and immunotherapies

Published:2017-02-06 Issue:3 Volume:27 Page:477-494
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Chiuzan Cody¹,Shtaynberger Jonathan¹,Manji Gulam A.²,Duong Jimmy K.¹,Schwartz Gary K.²,Ivanova Anastasia³,Lee Shing M.¹

Affiliation:

1. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA

2. Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, New York, USA

3. Department of Biostatistics, UNC at Chapel Hill, Chapel Hill, North Carolina, USA

Funder

American Cancer Society

National Institutes of Health

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2017.1289952

Reference136 articles.

1. Cancer phase I clinical trials: efficient dose escalation with overdose control

2. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors

3. The bivariate continual reassessment method

4. Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies

5. Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies;Clinical Trials;2024-04-15

2. In Curative Stereotactic Body Radiation Therapy for Prostate Cancer, There Is a High Possibility That 45 Gy in Five Fractions Will Not Be Tolerated without a Hydrogel Spacer;Cancers;2024-04-11

3. Enhancement of Bayesian optimal interval design by accounting for overdose and underdose errors trade-offs;Journal of Biopharmaceutical Statistics;2023-11-15

4. Determining drug dose in the era of targeted therapies: playing it (un)safe?;Blood Cancer Journal;2022-08-23

5. The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension;Nature Medicine;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3